Effect of Regional Citrate Anticoagulation on Thrombogenicity and Biocompatibility During CVVHDF

REFERENCES

• Kellum JA, Mehta RL, Angus DC, Palevsky P, Ronco C. The first international consensus conference on continuous renal replacement therapy. Kidney Int 2002; 62: 1855–1863, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ronco C, Zanella M, Brendolan A. Management of severe acute renal failure in critically ill patients: an international survey in 345 centres. Nephrol Dial Transplant 2001; 16: 230–237, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Manns M, Sigler MH, Teehan BP. Continuous renal replacement therapies: an update. Am J Kidney Dis 1998; 2: 185–207
   Google Scholar
• Reeves JH, Graan M. Randomized controlled trial enoxaparin versus heparin in continuous renal replacement therapy. Blood Purif 2003; 21: 183–207, [CROSSREF]
   Google Scholar
• Davenport A, Will EJ, Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron 1994; 66(4)431–437, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Schneider T, Heuer B, Deller A, Boesken WH. Continuous hemofiltration with r-hirudin (lepirudin) as anticoagulant in a patient with heparin induced thrombocytopenia (HIT II). Wien Klin Wochenschr 2000; 112(12)552–555, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ohtake Y, Hirasawa H, Sugai T, et al. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol 1991; 93: 215–217, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Cointault O, Kamar N, Bories P, et al. Regional citrate anticoagulation in continuous venovenous hemodiafiltration using commercial solutions. Nephrol Dial Transplant 2004; 19: 171–178, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Tolwani AJ, Campbell RC, Schenk MB, Allon M, Warnock DG. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int 2001; 60: 370–374, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Swartz R, Pasko D, O'Toole J, Starmann B. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin Nephrol 2004; 61(2)134–143, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kutsogiannis JD, Mayers I, Nin Chin WD, Gibney N. Regional citrate anticoagulatinon in continuous venovenous hemodiafiltration. Am J Kidney Dis 2000; 35: 802–811, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Zemanová P, Opatrný K, Jr, Polanská K, et al. Is it appropriate to tune regional citrate anticoagulation during hemodialysis by ionized calcium levels?. Blood Purif 2005; 23: 407
   Web of Science ®Google Scholar
• Opatrný K, Jr, Polanská K, Kroužecký A, Vít L, Novák I, Kasal E. The effect of heparin rinse on the biocompatibility of continuous veno-venous hemodiafiltration. Int J Artif Organs 2002; 25(6)520–528
   PubMed Web of Science ®Google Scholar
• Salmon J, Cardigan R, Mackie I, Cohen SL, Machin S, Singer M. Continuous venovenous hemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation pathways. Intensive Care Med 1997; 23: 38–43, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Stefanidis I, Hägel J, Kierdorf H, Maurin N. Influencing hemostasis during continuous venovenous hemofiltration after acute renal failure: comparison with intermittent hemodialysis. Contrib Nephrol 1995; 116: 140–144, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Cardigan RA, McGloin H, Mackie IJ, Machin J, Singer M. Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. Kidney Int 1999; 55: 1568–1574, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Cheung AK, Faezi-Jenkin B, Leypoldt JK. Effect of thrombosis on complement activation and neutrophil degranulation during in vitro hemodialysis. J Am Soc Nephrol 1994; 5(1)110–115, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Tayama E, Hayashida N, Akasu K, et al. Biocompatibility of heparin-coated extracorporeal bypass circuits: new heparin bonded bioline system. Int J Artif Organs 2000; 24: 618–623, [CROSSREF]
   Google Scholar
• Bos JC, Grooteman MPC, van Houte AJ, Schoorl M, van Limbeek J, Nubé MJ. Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. Nephrol Dial Transplant 1997; 12: 1387–1393, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Plötz FB, van Oeveren W, Hultquist KA, Miller C, Bartlett RH, Wildevuur CRH. A heparin-coated circuit reduces complement activation and the release of leukocyte inflammatory mediators during extracorporeal circulation in a rabbit. Int J Artif Organs 1992; 16: 366–370
   Google Scholar
• Schrefl A, Kellner K-H, Hartmann J, Strobl W, Falkenhagen D. A novel monitor for anticoagulation with citrate. Int J Artif Organs 2001; 24: 535
   Google Scholar
• Charney DI, Salmond R. Cardiac arrest after hypertonic citrate anticoagulation for chronic hemodialysis. ASAIO Trans 1990; 36: M217–M219, [PUBMED], [INFOTRIEVE]
   Google Scholar
• Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990; 38: 976–981, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30(2)260–265, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kutsogiannis DJ, Gibney RTN, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361–2367, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tobe SW, Aujla P, Walele AA, et al. A novel regional citrate anticoagulation protocol for CRRT using only commercially available solutions. J Crit Care 2003; 18: 121–129, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gabutti L, Marone C, Colucci G, Duchini F, Schönholzer C. Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med 2002; 28: 1419–1425, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Opatrný K, Jr, Vít L, Opatrná S, et al. Hemocompatibility in hemodialysis and erythropoietin therapy. Artif Organs 1995; 19(8)814–820
   PubMed Web of Science ®Google Scholar
• Frank RD, Weber J, Dresbach H, Thelen H, Weiss C, Floege J. Role of contact system activation in hemodialyzer-induced thrombogenicity. Kidney Int 2001; 60: 1972–1981, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ivanovich P, Hammerschmidt DE, Quintanilla A, et al. Behaviour of platelets and beta-thromboglobulin. Nephrol Dial Transplant 1993; 8(suppl 2)15–19, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Silvester W, Honoré P, Sieffert E, et al. Interleukins 6 and 8, tumour necrosis factor alpha and complement D clearance by polyacrylonitrile and polysulphone membranes during hemofiltration in critically ill patients. Presented at: Continuous Hemofiltration in Intensive Care Meeting, Paris, 1996
   Google Scholar
• van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996; 7: 145–150, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bohler J, Schollmeyer P, Dressel B, Dobos G, Horl WH. Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation. J Am Soc Nephrol 1996; 7: 234–241, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Gabutti L, Ferrari N, Mombelli G, Keller F, Marone C. The favourable effect of regional citrate anticoagulation on interleukin-1beta release is dissociated from both coagulation and complement activation. J Nephrol 2004; 17: 819–825, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Wiegmann TB, McDougall ML, Diederich DA. Dialysis leukopenia, hypoxemia, and anaphylatoxin formation: effect of membrane, bath, and citrate anticoagulation. Am J Kidney Dis 1988; 11: 418–424, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Wegmuller E, Montandon A, Nydegger U, Descoeudres C. Biocompatibility of different hemodialysis membranes: activation of complement and leukopenia. Int J Artif Organs 1986; 9: 85–92, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Cheung AK, Parker CJ, Wilcox LA, Janatova J. Activation of complement by hemodialysis membranes: polyacrylonitrile binds more C3a than cuprophan. Kidney Int 1990; 37: 1055–1059, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Hoenich NA, Woffindin C, Brennan A, Cox PJ, Matthews JN, Goldfinch M. A comparison of three brands of polysulfone membranes. J Am Soc Nephrol 1996; 7: 871–876, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Davenport A. The coagulation system in the critically ill patient with acute renal failure and the effect of an extracorporeal circuit. Am J Kidney Dis 1997; 30(5, suppl. 4)S20–S27, [PUBMED], [INFOTRIEVE]
   Web of Science ®Google Scholar